These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 19938897)

  • 1. Assessment of the cardiac safety of fampridine-SR sustained-release tablets in a thorough QT/QTc evaluation at therapeutic and supratherapeutic doses in healthy individuals.
    March B; Cardi T
    Expert Opin Investig Drugs; 2009 Dec; 18(12):1807-15. PubMed ID: 19938897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: a Phase I-II, open-label trial.
    Vollmer T; Henney HR
    Clin Ther; 2009 Oct; 31(10):2206-14. PubMed ID: 19922891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study.
    Vollmer T; Blight AR; Henney HR
    Clin Ther; 2009 Oct; 31(10):2215-23. PubMed ID: 19922892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sugammadex is not associated with QT/QTc prolongation: methodology aspects of an intravenous moxifloxacin-controlled thorough QT study.
    de Kam PJ; van Kuijk J; Smeets J; Thomsen T; Peeters P
    Int J Clin Pharmacol Ther; 2012 Aug; 50(8):595-604. PubMed ID: 22735462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A placebo- and active-controlled assessment of 6- and 50-mg oral doxepin on cardiac repolarization in healthy volunteers: a thorough QT evaluation.
    Mansbach RS; Ludington E; Rogowski R; Kittrelle JP; Jochelson P
    Clin Ther; 2011 Jul; 33(7):851-62. PubMed ID: 21722958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.
    Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A
    Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study.
    Zhang L; Chappell J; Gonzales CR; Small D; Knadler MP; Callaghan JT; Francis JL; Desaiah D; Leibowitz M; Ereshefsky L; Hoelscher D; Leese PT; Derby M
    J Cardiovasc Pharmacol; 2007 Mar; 49(3):146-53. PubMed ID: 17414226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose comparison trial of sustained-release fampridine in multiple sclerosis.
    Goodman AD; Brown TR; Cohen JA; Krupp LB; Schapiro R; Schwid SR; Cohen R; Marinucci LN; Blight AR;
    Neurology; 2008 Oct; 71(15):1134-41. PubMed ID: 18672472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety profile of dalfampridine extended release in multiple sclerosis clinical trials.
    Cornblath DR; Bienen EJ; Blight AR
    Clin Ther; 2012 May; 34(5):1056-69. PubMed ID: 22497693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of vardenafil and sildenafil on cardiac repolarization.
    Morganroth J; Ilson BE; Shaddinger BC; Dabiri GA; Patel BR; Boyle DA; Sethuraman VS; Montague TH
    Am J Cardiol; 2004 Jun; 93(11):1378-83, A6. PubMed ID: 15165918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers.
    Hofmann C; Banken L; Hahn M; Swearingen D; Nagel S; Martin-Facklam M
    Clin Ther; 2012 Oct; 34(10):2061-71. PubMed ID: 22980315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single-dose, crossover, placebo- and moxifloxacin-controlled study to assess the effects of neratinib (HKI-272) on cardiac repolarization in healthy adult subjects.
    Hug B; Abbas R; Leister C; Burns J; Sonnichsen D
    Clin Cancer Res; 2010 Aug; 16(15):4016-23. PubMed ID: 20647478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of a supratherapeutic dose of investigational orally inhaled dihydroergotamine (MAP0004) on QT interval: a randomized, double-blind, active- and placebo-controlled crossover study in healthy volunteers.
    Kori S; Kellerman DJ; Voloshko P; Haugen G
    Clin Ther; 2012 Sep; 34(9):1920-8. PubMed ID: 22917853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raltegravir thorough QT/QTc study: a single supratherapeutic dose of raltegravir does not prolong the QTcF interval.
    Iwamoto M; Kost JT; Mistry GC; Wenning LA; Breidinger SA; Marbury TC; Stone JA; Gottesdiener KM; Bloomfield DM; Wagner JA
    J Clin Pharmacol; 2008 Jun; 48(6):726-33. PubMed ID: 18441333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of effect of aprepitant or its prodrug fosaprepitant on QTc intervals in healthy subjects.
    Marbury TC; Jin B; Panebianco D; Murphy MG; Sun H; Evans JK; Han TH; Constanzer ML; Dru J; Shadle CR
    Anesth Analg; 2009 Aug; 109(2):418-25. PubMed ID: 19608812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study.
    Goodman AD; Cohen JA; Cross A; Vollmer T; Rizzo M; Cohen R; Marinucci L; Blight AR
    Mult Scler; 2007 Apr; 13(3):357-68. PubMed ID: 17439905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained-release fampridine for symptomatic treatment of multiple sclerosis.
    Korenke AR; Rivey MP; Allington DR
    Ann Pharmacother; 2008 Oct; 42(10):1458-65. PubMed ID: 18780812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of a single supratherapeutic dose of dolutegravir on cardiac repolarization.
    Chen S; Min SS; Peppercorn A; Borland J; Lou Y; Song I; Fujiwara T; Piscitelli SC
    Pharmacotherapy; 2012 Apr; 32(4):333-9. PubMed ID: 22422361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thorough QT study with recommended and supratherapeutic doses of tolterodine.
    Malhotra BK; Glue P; Sweeney K; Anziano R; Mancuso J; Wicker P
    Clin Pharmacol Ther; 2007 Mar; 81(3):377-85. PubMed ID: 17339867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of QTc prolongation with betrixaban: a randomized, double-blind, placebo- and positive-controlled thorough ECG study.
    Morganroth J; Gretler DD; Hollenbach SJ; Lambing JL; Sinha U
    Expert Opin Pharmacother; 2013 Jan; 14(1):5-13. PubMed ID: 23216423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.